GlassScriptPhysician profile
Hana Kim
NPI 1760719348
$8,420.28
in general payments reported to CMS, 2019-2025
45 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $1,408 · 2023: $2,316 · 2024: $1,846 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,691 · Entertainment: $14.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,691.10 |
| Entertainment | $14.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,737.34 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,350.04 | 2021-2025 | Descovy, Biktarvy |
| Glaxosmithkline, LLC. | $713.09 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $514.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $462.35 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Pfizer INC. | $438.04 | 2022-2025 | |
| Novo Nordisk INC | $336.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $320.93 | 2022-2025 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $285.93 | 2021-2023 | Symtuza |
| Lilly USA, LLC | $245.20 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Merck Sharp & Dohme LLC | $244.95 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Amgen INC. | $194.99 | 2024-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.55 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $162.59 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $119.35 | 2022-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $96.52 | 2022-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $85.38 | 2022 | |
| Janssen Products, LP | $80.80 | 2023 | Symtuza |
| Sumitomo Pharma America, INC. | $61.69 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.59 | 2022-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $57.13 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $45.99 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $44.60 | 2025 | |
| Napo Pharmaceuticals INC | $43.77 | 2023 | Mytesi |
| Corcept Therapeutics | $42.78 | 2023 | Korlym |
| Organon LLC | $39.67 | 2023-2024 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.16 | 2024 | Relistor |
| Theratechnologies INC. | $35.35 | 2024 | Egrifta, Trogarzo |
| Insightec,INC | $32.62 | 2023 | Exablate |
| Organogenesis INC. | $30.25 | 2025 | Puraply Wound Matrix |
| Amarin Pharma, INC. | $28.16 | 2021 | |
| Siemens Medical Solutions USA, INC. | $26.91 | 2025 | Immulite 1000 Immunoassay System |
| Nevro Corp. | $25.92 | 2023 | Senza |
| Daiichi Sankyo INC. | $23.36 | 2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $21.65 | 2023 | Strensiq |
| Invivyd INC | $20.47 | 2024 | Pemgarda |
| Biohaven Pharmaceuticals, INC. | $20.45 | 2021 | |
| Convatec INC. | $20.34 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.20 | 2025 | Voquezna |
| Boston Scientific Corporation | $19.28 | 2025 | Wavewriter Alpha Prime 16 |
| Halozyme INC | $18.77 | 2023 | |
| Zimmer Biomet Holdings, INC. | $18.62 | 2025 | Persona |
| Cranial Technologies, INC | $14.86 | 2025 | Doc Band |
| Vbi Vaccine (Delaware) INC. | $14.65 | 2022 | |
| Optos, INC. | $14.09 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hana Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.